Anti-Cancer (Oncology)
| Product Name | CAS No. | Specification | Application | Registration |
| Osimertinib mesylate | 1421373-66-1 | 98+% | Anti-cancer | EGFR | |
| Osimertinib | 1421373-65-0 | 98+% | Anti-cancer research | EGFR | |
| Midostaurin | 120685-11-2 | 98+% | Anticancer Research | |
| R428 (BGB324; Bemcentinib) | 1037624-75-1 | 98+% | Axl inhibitor | |
| Alectinib | 1256580-46-7 | 98+% | ALK inhibitor | |
| AOH1996 | 2089314-64-5 | 98+% | DNA/RNA Synthesis inhibitor | |
| Clofarabine | 123318-82-1 | 99+% | Anti-cancer | | Nucleoside Antimetabolite/Analog | |
| Capecitabine | 154361-50-9 | 99+% | Anti-cancer | DNA/RNA Synthesis inhibitor | Apoptosis related activator | |
| Irinotecan Hydrochloride Trihydrate | 136572-09-3 | 99+% | ||
| Ubenimex Hydrochloride | 65391-42-6 | |||
| Ubenimex (Bestatin) | 58970-76-6 | 98+% | CD13/APN inhibitor, has anti-cancer properties. | |
| (S)-(+)-Camptothecin (CPT) | 7689-03-4 | 98+% | ADC Cytotoxin inhibitor | Topoisomerase inhibitor | Apoptosis related activator | MicroRNA inhibitor | |
| Ibrutinib (PCI-32765) | 936563-96-1 | 98+% | ||
| Temsirolimus (CCI-779) | 162635-04-3 | 98+% | mTOR inhibitor | Autophagy activator | Apoptosis related activator | |
| Trastuzumab (anti-HER2) | 180288-69-1 | 95+% | EGFR | ADC Antibody |Antineoplastic Agent |the treatment of HER2 receptor positive breast cancer |
Products
- All
- Pharmaceutical Intermediates
- Active Pharmaceutical Ingredients
- Anti-Cancer (Oncology)
- Vitamin D Series Compounds
- Antibody-Drug Conjugates
- Prostaglandins
- Immunosuppressants
- Cardiovascular
- Antiviral Agents
- Anti-Diabetic
- Peptides
- Veterinary
- Antibacterial
- Miscellaneous
- Drug Impurities & Metabolites
- Novel Life Science Reagents
- Amino Acids & Vitamins
- Natural Products
- Health & Nutritional Ingredients
- Pharmaceutical Excipients
- Specialty Chemicals & Building Blocks
Custom Synthesis-High Value-Added Advanced Pharmaceutical Intermediates
E-Mail: sales (at)Chemleader.com.cn
E-Mail: sales (at)Chemleader.com.cn